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SUMMARY
Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma
patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of VEGF receptors—
has rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating
edema. Reversal of normalization began by 28 days, though some features persisted for as long
as four months. Basic FGF, SDF1a, and viable circulating endothelial cells (CECs) increased when
tumors escaped treatment, and circulating progenitor cells (CPCs) increased when tumors pro-
gressed after drug interruption. Our study provides insight into different mechanisms of action of
this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination
therapy may be critical for optimizing activity against this tumor.INTRODUCTION
Tumor vessels are structurally and functionally abnormal.
This abnormality impairs effective delivery of therapeutic
agents to all regions of tumors, creates an abnormal mi-
croenvironment (e.g., hypoxia) that reduces the effective-ness of radiation and chemotherapy, and selects for more
malignant cells. Antiangiogenic therapy has the potential
to normalize structurally and functionally abnormal tumor
vasculature and improve the tumor microenvironment
(Jain, 2001, 2005). However, when normalization begins
or ends in cancer patients treated with antiangiogenicSIGNIFICANCE
This study identifies the onset and duration of a vascular normalizationwindow created by an antiangiogenic agent
in a human tumor. These findings also provide evidence that recurrent glioblastomas remain responsive to anti-
angiogenic therapy following progression during drug interruption. Moreover, viable CECs, which correlated
with tumor progression through treatment, constitute different biomarkers thanCPCs,which correlatedwith tumor
relapse after drug interruption. On the other hand, plasma bFGF and SDF1a levels increase with tumor progres-
sion, highlighting these angiogenic pathways as potential targets for therapy. Finally, this study demonstrated
that AZD2171, amultitargeted tyrosine kinase inhibitor, can alleviate edema, amajor cause ofmorbidity in glioblas-
toma, and is associated with a steroid-sparing effect in these patients.Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 83
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Normalization of Glioblastoma Vasculature in PatientsFigure 1. Design of Clinical Trial and
Target Validation by Immunohistochem-
istry
(A) Trial schema. Dots indicate time points of
data collection. AZD2171 was administered
during the period shaded red.
(B) Representative immunohistochemistry
of glioblastoma endothelium. As expected,
VEGFR2 and PDGFRa are expressed in the
endothelial cells. Interestingly, PDGFRb is
also highly expressed in endothelial cells.
(Bar represents 100 mm for all images.)agents and whether this process is reversible are not
known (Jain et al., 2006). The specifics of how vascular
normalization directly benefits cancer patients are also
unclear. Finally, it is also not known if vascular normaliza-
tion can be detected with currently available imaging or if it
requires emerging new noninvasive technology or blood
biomarkers. Answering these questions is critical for
optimally combining antiangiogenic therapy with cyto-
toxic therapies and for customizing treatment for individ-
ual patients.
To this end, we designed a National Cancer Institute-
sponsored phase II clinical trial of AZD2171 (cediranib,
AstraZeneca Pharmaceuticals, UK; Wedge et al.,
2005)—a potent oral, pan-VEGF receptor tyrosine kinase
inhibitor with activity against PDGF receptors and
c-Kit—in glioblastoma patients who had failed conven-
tional therapy. Since serial tumor sampling is not possible
in brain tumor patients, we measured relative vessel size
and permeability, tumor contrast enhancement, and
edema-associated parameters in 16 consecutive patients
using a series of MRI protocols. Furthermore, we corre-
lated the temporal changes in these parameters with
blood molecular (angiogenic cytokines) and cellular (viable
CECs and CPCs) biomarkers of vascular response (trial
schema; Figure 1A). Our data show that AZD2171 induced
vascular normalization in recurrent glioblastomas within
24 hr, that vascular normalization lasted at least
28 days—ideal for combining with a cycle of concurrent
chemotherapy or radiotherapy—and that a direct conse-
quence of vascular normalization is alleviation of vaso-
genic brain edema. Strikingly, tumor vessels became ab-
normal following drug ‘‘holidays’’ and ‘‘renormalized’’ after
drug resumption. Disease progression during treatment
correlated with significant increases in plasma bFGF,
SDF1a, and viable CEC concentration. In contrast, tumor
progression after drug holidays correlated with increased84 Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc.CPC levels. These data not only identify potential new tar-
gets for recurrent glioblastoma treatment, but also show
that different circulating cell populations (CECs versus
CPCs) have value as independent biomarkers in patients
with recurrent glioblastoma treated with AZD2171.
RESULTS AND DISCUSSION
The Targets of AZD2171 Are Present in Recurrent
Glioblastoma Vessels
To determine if the targets of AZD2171 are present in glio-
blastoma, we performed immunohistochemistry on archi-
val tumor specimens from our subjects obtained at the
time of their original diagnosis. VEGFR2, PDGFRa, and
PDGFRb were present on the majority of endothelial cells
in all 16 patients, whereas VEGFR1 and VEGFR3 were
rarely detectable (Figure 1B). Although we could not
obtain biopsy tissue from these patients at the time of re-
currence, it is likely that expression patterns were not dra-
matically affected by prior radiation and chemotherapy.
Indeed, in a separate study of glioblastoma patients in
which matched pre- and posttreatment specimens were
available, the patterns of expression were similar, with
a concordance of 100% for the vascular expression of
VEGFR2, PDGFRa, and PDGFRb (overall level of concor-
dance for all AZD2171 targets: 76%) between newly diag-
nosed and recurrent tumor specimens (Tables S1 and S2
[see the Supplemental Data available with this article
online]). Collectively, these data suggest that VEGFR2,
PDGFRa, and PDGFRb—targets for agents such as
AZD2171—are present in recurrent glioblastoma.
Recurrent Glioblastomas Respond to AZD2171
Treatment
Since AZD2171’s targets are consistently present on the
endothelium in glioblastoma, and the half-life of
Cancer Cell
Normalization of Glioblastoma Vasculature in PatientsAZD2171 (12.5–35.4 hr) allows their continuous inhibition
with daily administration, we anticipated this agent would
be a potent antivascular and normalizing agent. Indeed, all
patients showed decreased tumor contrast enhance-
ment (using gadolinium as a tracer) after a single dose
of AZD2171 despite an aggressive growth rate of approx-
imately 1% in tumor enhancement volume per day prior to
treatment initiation (Figure S1 and Tables S3 and S4). Us-
ing volumetric evaluation methods (Sorensen et al., 2001),
we detected a decrease in tumor enhancement of more
than 50% in 9/16 patients and 25%–50% in 3/16
patients (Figures 2–4 and 5A, and Table S5). Toxicity
was modest, and median progression-free survival in
this small cohort of patients was 111 days, which com-
pares favorably to that reported from an historical
database (Wong et al., 1999) (Figure 6). Similar to other
antiangiogenic therapies that target only tumor endothe-
lium, monotherapy with AZD2171 may not improve over-
all survival, suggesting the need to combine cytotoxic
therapies with AZD2171 (median overall survival in our
16 patients was 211 days, compared to a median overall
survival of 175 days from an historical database [Wong
et al., 1999]).
Despite detection of the targets of AZD2171 in the
glioblastoma vasculature in all of our patients, there was
considerable variability in tumor responses (Figures 2–5,
and Tables S3 and S4). Thus, identification of biomarkers
associated with tumor regression is a high priority. The
radiographic regressions observed in our study but appar-
ent lack of survival prolongation emphasizes the need
for combination studies with AZD2171. It also suggests
that the traditional endpoint of tumor enhancement vol-
ume may not be the optimal assessment of treatment
response. Establishing the optimal timing of antiangio-
genic therapies such as AZD2171 in relation to other cyto-
toxic therapies is a critical challenge (Brown et al., 2004;
Grossman and Batara, 2004; Jain et al., 2006; Prados
et al., 2006; Reardon et al., 2005; Tremont-Lukats and
Gilbert, 2003).
AZD2171 Induces a Rapid Structural Normalization
of Tumor Vessels
In preclinical studies, fractionated radiation or chemother-
apeutics are most effective when given during a window of
normalization created by antiangiogenic agents (Ansiaux
et al., 2005; Segers et al., 2006; Winkler et al., 2004). In
a clinical trial in rectal carcinoma patients, a single admin-
istration of bevacizumab—a VEGF-specific antibody with
a half-life of 2–3 weeks—has been shown to prune ap-
proximately half of the tumor vessels and normalize the re-
maining vasculature by day 12 (Willett et al., 2004, 2005).
Key challenges now are to identify the beginning and end
of this process and to determine the impact of normaliza-
tion on the tumor. In murine models, VEGFR2- and VEGF-
blockade or downregulation begin to normalize the tumor
vasculature by day 1 or 2, as detected by a significant de-
crease in their mean vessel diameter and permeability
(Jain et al., 1998; Kadambi et al., 2001; Tong et al.,
2004; Winkler et al., 2004; Yuan et al., 1996). Unlike vascu-lar permeability, tumor vessel size during antiangiogenic
therapy has never been reported in cancer patients.
The MRI methods (Dennie et al., 1998; Schmainda et al.,
2004) used here demonstrate that in most patients, similar
to mouse models, relative tumor vessel size significantly
decreased as early as 1 day after the onset of AZD2171
treatment (p < 0.05), and it remained decreased at day
28. At day 56, the relative vessel size reverses toward
abnormal values (p < 0.05 versus day 28 values) in the ma-
jority of patients, suggesting the beginning of the closure
of the structural vascular normalization window (Figures
3, 4, and 5A, and Figure S2 and Table S3). Our MRI
method separately measures blood volume in large and
small vessels, where small means a peak sensitivity to
vessels 5–10 microns in diameter, and large means all
vessels weighted equally. AZD2171 has a more pro-
nounced effect on large microvessels compared to small
microvessels, with an immediate decrease in blood vol-
ume in large vessels, and decreased blood flow in both
small and large vessels (Table S3). These results demon-
strate a direct effect of AZD2171 on tumor vasculature,
which may be due to vessel pruning and remodeling
and/or blockade of angiogenesis.
AZD2171 Induces a Rapid Onset of Functional
Vascular Normalization
VEGF is a potent vascular permeability factor (Dvorak,
2002; Senger et al., 1983). Similar to previous preclinical
and clinical studies, we found a significant reduction in
vascular permeability (as measured by the transfer con-
stant Ktrans of contrast agent between plasma and the
extravascular extracellular space) (Jackson et al., 2003;
Pope et al., 2006; J. Drevs et al., 2005, J. Clin. Oncol., ab-
stract) at days 1 and 28 (p < 0.01). Unlike the increase in
vessel size, vascular permeability to gadolinium remained
decreased through day 112, indicating that this feature of
vascular normalization extended beyond 56 days (Figures
2C and 5A, and Table S3). This uncoupling between vessel
size and permeability during AZD2171 therapy was not
observed in preclinical studies of therapies that exclu-
sively target the VEGF pathway in glioblastoma (Winkler
et al., 2004) and may be a consequence of the broader
inhibitory spectrum of AZD2171.
Formally, Ktrans is not solely permeability dependent; it
represents a function of both permeability and vessel sur-
face area. Consequently, the significant drop in Ktrans
could be due, in part, to reduced vascular surface area if
vessels are shrinking. However, with uncoupling, and a re-
bound in vessel size, the persistent decrease in Ktrans indi-
cates that permeability remains reduced. We observed
a correlation between uncoupling and elevation of bFGF
and SDF1a levels (see below), suggesting that these cyto-
kines may be involved in this process. Although c-Kit
expression was not commonly detected in glioblastoma
tumor cells or vessels, a systemic effect cannot be ex-
cluded, as c-Kit is present and functional in CPCs (Rafii
et al., 2002). Also, PDGF receptors were expressed along
with VEGFR2 on the endothelial cells of all glioblastomas
examined (Figure 1B). However, the effects of PDGFRbCancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 85
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Normalization of Glioblastoma Vasculature in PatientsFigure 2. Representative Images from the Best-Responding Patient, Patient 9
(A) T1-weighted anatomic images after intravenous administration of a contrast agent (gadolinium-DTPA), demonstrating a region of bright signal
corresponding to the recurrent brain tumor in the left frontal lobe shrinking over time (all images are displayed per standard radiographic convention).
Note also the decreased mass effect on the left lateral ventricle.
(B) Map of relative microvessel size, also showing decrease over time.
(C) Maps of Ktrans, a measure of blood-brain barrier permeability. Note the substantial change after the first dose.
(D) T2-weighted images acquired with a fluid-attenuated inversion recovery sequence (FLAIR), where edema is seen surrounding the tumor enhance-
ment evident in (A), also decreasing over time.
(E) Images of apparent diffusion coefficient (ADC) demonstrating water mobility, which identifies areas of vasogenic edema as high (bright) signal
surrounding the region of enhancing tumor; these also reduce over time. The displacement of the ventricle is also reduced over time.
(F) Tractography. These images demonstrate directional water mobility suggesting the presence of white matter tracts. As the vasogenic edema
decreases and the mass effect subsides, these white matter tracts become more evident. A movie of day 1 and day 28 time points is available
in the Supplemental Data (Movie S1).86 Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc.
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Normalization of Glioblastoma Vasculature in PatientsFigure 3. Representative Images from a Moderately Responding Patient
(A–F) The types of images are the same as in Figure 2. Typical of most patients, there was substantial and prolonged reduction of enhancement and
peritumoral edema, with some rebound of vessel size at day 55.signaling blockade by AZD2171 in endothelial and peri-
vascular cells remain to be elucidated. Similarly, it would
be of great interest to establish any direct effect ofAZD2171 on glioblastoma cells and, in particular, on the
cancer stem cells (Fomchenko and Holland, 2006), which
may be responsible for tumor relapse.Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 87
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Normalization of Glioblastoma Vasculature in PatientsFigure 4. Representative Images from the Worst-Responding Patient
(A–F) The types of images are the same as in Figure 2. This patient had no substantial reduction in permeability, mass effect, or vessel size. A slight
decrease in edema is evident on the FLAIR and ADC images at day 27, but this reverts by day 55.Vascular Normalization by AZD2171 Alleviates
Vasogenic Edema
A direct consequence of the vascular abnormalities in glio-
blastoma is vasogenic brain edema, which is a significant
cause of morbidity in these patients. The most widely used88 Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc.and effective therapy for vasogenic edema is corticoste-
roid administration. However, corticosteroid-related com-
plications are frequent and detrimental for glioblastoma
patients. Preclinical studies have demonstrated that
VEGF blockade can reduce edema due to ischemic injury
Cancer Cell
Normalization of Glioblastoma Vasculature in PatientsFigure 5. Changes in Imaging Parame-
ters over Time
(A) Median values for contrast-enhanced
T1-weighted tumor volume (CE-T1), vessel
size (VS), and permeability (P) of the tumor
over time as measured by an independent
expert. Day 1 was set as 100% in all lesions,
and changes during AZD2171 treatment were
plotted for all 16 patients. Note the rebound
of CE-T1 volume and vessel size after day 28,
which indicates a partial closure of the normal-
ization window.
(B) Median values of T2-weighted abnormality
volume measured in fluid-attenuated inversion
recovery images (FLAIR), apparent diffusion
coefficient (ADC), and extracellular-extravas-
cular volume fraction (ve) prior to and during
treatment showing a sustained decrease of
edema while taking AZD2171. (*p < 0.05 for
values compared with day 1; #p < 0.05 for
values compared with day +1. For full
measurement details see Table S3.)(Weis and Cheresh, 2005). Whether VEGF blockade could
reduce vasogenic edema in brain tumor patients has not
been quantitatively assessed. Therefore, we used three
different MRI techniques to assess and quantify vaso-
genic brain edema in our study: (1) T2-weighted fluid-
attenuated inversion recovery (FLAIR) lesion volumes; (2)
trace apparent diffusion coefficient of water (ADC); and
(3) extracellular extravascular space fraction (ve). (Figures
2–4, and Figure S2 and Table S3). All these measurements
demonstrated rapid and significant reduction in vasogenic
edema for the duration of AZD2171 therapy (p < 0.01;
Figure 5B). Consequently, 14 of 15 patients with mass
effect (e.g., displacement of ventricles, midline shift) due
to their recurrent tumor showed reduction in the mass
effect and improvement in the visibility of white matter
fiber anatomy (Figures 2–4, and Movie S1).
Steroid usage was reduced in these subjects compared
to typical recurrent glioblastoma patients. Five patients
did not require steroids, and of the 11 patients who
received corticosteroids during the course of AZD2171
therapy, 8 had their dose reduced and 3 had corticoste-
roids discontinued. All patients who progressed on this
study required corticosteroids after discontinuation of
AZD2171. These data demonstrate that AZD2171—and
the resulting vascular normalization—efficiently de-
creases edema in glioblastoma patients and is associatedwith a steroid-sparing effect in this population. Corticoste-
roids are not only associated with detrimental side effects
in cancer patients but may also diminish the effectiveness
of chemotherapy. Dexamethasone has been shown
in vitro to reduce the efficacy of concurrently administered
chemotherapy (Das et al., 2004). The antiedema effects of
AZD2171 may improve neurological function and allow
better clinical tolerance of fractionated radiation, since
well-known adverse effects of radiation are brain/tumor
necrosis and exacerbation of vasogenic edema with
increased intracranial pressure. There is anecdotal evi-
dence that standard chemoradiation (temozolomide and
fractionated radiation) may increase the risk of tumor
necrosis and brain edema (Chamberlain et al., 2006).
Thus, for multiple reasons the combination of AZD2171
with chemoradiation in newly diagnosed glioblastoma
patients is worthy of investigation.
Vascular Normalization by AZD2171 Is Reversible
Since some patients required drug interruption due to
toxicity (referred to as a drug holiday; see Table S6), we
used this opportunity to gain further mechanistic insight
into vessel normalization. Radiographic analyses pro-
vided evidence that drug holidays were associated with
an increase in the CE-T1 volume (Figure 7A); of note,
drug holidays within 14 days of a scheduled MRI wereFigure 6. Kaplan-Meier Survival Distri-
butions
(A) Progression-free survival and (B) overall
survival in sixteen recurrent glioblastoma
patients receiving AZD2171 (bold red lines)
accompanied by upper and lower 95%
confidence limits (thin black lines).Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 89
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Normalization of Glioblastoma Vasculature in PatientsFigure 7. Reversibility of Normalization
(A) Vascular and volume changes as a function of time in a patient who did not take drug from days 43 through 56 and was imaged on day 55 (shown as
drug holiday). T1-weighted anatomic images after intravenous administration of gadolinium-DTPA, similar to Figure 2. Note that at day 55 there is
a rebound in tumor enhancement, which decreases again after restarting the drug as seen on follow-up imaging on day 110. In this patient, maps
of relative vessel size (similar to Figure 1C) also show fluctuation with the drug holiday and resumption of AZD2171 treatment.
(B) Measurements of imaging parameters confirm the reversibility of vascular normalization by drug interruption followed by renormalization after
AZD2171 is resumed.associated not only with a significant increase in the en-
hancement volume, but also in extracellular-extravascular
volume fraction (ve, p < 0.05; Table S7). Two of these five
patients (patients 4 and 10) underwent MRI studies before,
during, and after a drug holiday. In these two patients, the
enhancement volume and permeability were smaller than
baseline prior to the holiday, increased substantially
during the holiday, and then regressed again after the
holiday when AZD2171 was resumed (Figure 7B). These
data reveal the reversibility of AZD2171-induced vascular
normalization and the plasticity of human tumor vessels.
Circulating Biomarkers Correlate Differentially with
Tumor Response to AZD2171 Treatment
A major challenge in using antiangiogenic agents remains
identification and validation of molecular and cellular bio-
markers of response. Currently, no such parameters have
been discovered for bevacizumab (Ince et al., 2005; Jubb
et al., 2006). We examined molecular (angiogenic cyto-
kines and soluble receptors) and cellular (viable CECs
and CPCs) markers in patients who progressed while on
AZD2171 and in those who had drug holidays, and we
found significant changes. Consistent with previous re-
ports on the effects of anti-VEGF agents (Motzer et al.,
2006; Willett et al., 2005; J. Drevs et al., 2005, J. Clin. On-
col., abstract), our blood biomarker analyses showed
significant increases in VEGF and PlGF and decreases in
sVEGFR2 plasma levels throughout AZD2171 treatment
(Table S8). In patients who experienced tumor progres-
sion while on AZD2171, increases in tumor enhancement
volume were associated not only with decreases in levels
of PlGF and increases in sVEGFR2 in plasma, but also with
significant increases in plasma levels of bFGF and SDF1a
(p < 0.05; Table 1). Moreover, there was a statistically sig-
nificant (p < 0.05; Table 1) positive correlation between90 Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc.both bFGF and SDF1a levels and vessel size measured
by MRI. It has been previously reported that bFGF (a po-
tent mitogen for endothelial cells) can compensate for
VEGF and induce angiogenesis in transplanted tumors
(Yoshiji et al., 1997). These findings were also confirmed
recently in oncogene-induced insulinomas (Casanovas
et al., 2005). However, the clinical evidence for this com-
pensation has been lacking. In addition, preclinical and
clinical evidence has supported a critical role for SDF1a
in glioblastoma neovascularization (Aghi et al., 2006;
Rempel et al., 2000). Our work provides clinical evidence
that bFGF and SDF1a may play a role in glioblastoma
relapse in patients treated with anti-VEGF agents. Based
on these findings, we suggest that bFGF and SDF1a
should be considered as biomarkers as well as potential
targets for extending the normalization window.
Viable CECs and CPCs have been previously proposed
as biomarkers for antiangiogenic therapy, but a clear con-
sensus on the surface markers used to identify these
blood-circulating cells is currently lacking (Bertolini et al.,
2006; Duda et al., 2006). Subsets of CPCs (e.g., endothe-
lial and/or hematopoietic progenitors) have been sug-
gested to play an important role in angiogenesis (Rafii
et al., 2002; Stoll et al., 2003), and moreover, these cells
may represent targets for antiangiogenic therapy (Carme-
liet, 2005). Indeed, we have found that bevacizumab de-
creases the number of viable CECs and CPCs in rectal
carcinoma patients (Willett et al., 2004, 2005). But whether
viable CECs and CPCs are biomarkers of response to, or
progression through, antiangiogenic therapy in patients is
unclear. In addition, whether viable CECs play any role in
tumor neovascularization or during antiangiogenic ther-
apy is not currently known. In this study, we found that
viable CEC number increased significantly with tumor
enhancement volume measured by MRI at four time
Cancer Cell
Normalization of Glioblastoma Vasculature in PatientsTable 1. Blood Biomarker Analyses in Relation to Radiographic Tumor Response, Drug Holidays, and Vessel Size
Effect of Tumor
Progression Effect of Drug Holidays Effect on Vessel Size
VEGF 15% 43% 0.111
[32% to +7%] [58% to 22%] [0.159 to 0.381]
p = 0.1701 p = 0.0005 p = 0.4151
PlGF 32% 58% 0.023
[49% to 9%] [72% to 38%] [0.180 to 0.225]
p = 0.0094 p < 0.0001 p = 0.8224
sVEGFR1 +5% +10% 0.137
[8% to +21%] [8% to +31%] [0.593 to 0.319]
p = 0.4775 p = 0.2963 p = 0.5515
sVEGFR2 +13% +11% 0.002
[0% to +26%] [6% to +30%] [0.553 to 0. 549]
p = 0.0420 p = 0.2115 p = 0.8224
bFGF +59% +92% 0.138
[+2% to +148%] [3% to +280%] [0.008 to 0.268]
p = 0.0417 p = 0.0606 p = 0.0372
SDF1a +12% +4% 0.667
[+2% to +22%] [7% to +18%] [0.075 to 1.258]
p = 0.0158 p = 0.4794 p = 0.0227
Viable CECs +53% +11% 0.147
[+3% to +128%] [38% to +96%] [0.026 to 0.320]
p = 0.0347 p = 0.7283 p = 0.0945
CPCs 3% +75% 0.130
[29% to +34%] [+15% to +167%] [0.103 to 0.364]
p = 0.8741 p = 0.0097 p = 0.2683
Estimates are determined as described in Experimental Procedures and represent the percent change in plasma concentration
(for cytokines) or in circulating cells (CECs and CPCs) associated with a doubling in tumor volume assessed by CE-T1 imaging
(left column) or drug holiday (middle column); estimates in the right column represent mean absolute change in vessel size asso-
ciated with a doubling of the tested biomarker variable, after adjusting for time trend and initial vessel size. Square brackets present
95% confidence intervals for the point estimates. Significant correlations are depicted in bold and italics.points (days 1, 28, 56, and 112) during AZD2171 therapy
(p < 0.05; Table 1). In addition, viable CEC levels were
higher in the patients who experienced disease progres-
sion during AZD2171 therapy (n = 11) compared to
patients without progression at day 112 (n = 5; median
peak values 1.58 and 0.95, respectively, evaluated at all
eight time points before and after AZD2171 treatment,
p < 0.05). No such correlation was seen for CPCs.
After drug holidays VEGF and PlGF plasma levels de-
creased significantly (p < 0.01; Table 1). Interestingly,
blood biomarker analyses after drug holidays also showed
that glioblastoma progression (as measured by MRI) after
the interruption of AZD2171 therapy correlated with signif-
icant increases in the number of CPCs (p < 0.01) and with
a trend toward increased plasma bFGF (Table 1). These
findings suggest a differential role for CPCs versus viable
CECs in the assessment of clinical outcomes in recurrentglioblastoma. These data also emphasize the critical
importance of using multiple viability and cell surface
markers to identify these distinct populations and differen-
tiate them from other blood circulating cells, such as non-
viable CECs (likely shed by the tumor endothelium during
therapy) or mature hematopoietic cells (Duda et al., 2007).
In contrast, bFGF and SDF1a appear to be more generic
biomarkers of glioblastoma relapse. Of interest, the
expression of AZD2171’s targets (VEGF and PDGF recep-
tors or c-Kit) on tumor cells from the initial biopsy speci-
men did not correlate with response in these recurrent
glioblastoma patients.
Conclusion
In summary, we report an immediate and significant
normalizing effect of AZD2171 in 16 patients with recur-
rent glioblastoma—indicative of a direct effect on tumorCancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 91
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marker correlations. The sustained reduction in perme-
ability is associated with a reduction in tumor-associated
vasogenic brain edema and clinical benefit in most
patients as measured by avoidance or reduction of corti-
costeroids. The antiedema effects of AZD2171 observed
in our study raise the possibility that anti-VEGF therapies
might prove beneficial for vasogenic brain edema second-
ary to primary and metastatic brain tumors or other neuro-
logical diseases. Other features of vascular normalization
(e.g., decreased blood vessel size) were maintained for at
least 28 days, which suggests that administration of
AZD2171—or potentially other VEGF inhibitors—with
concurrent cytotoxic therapies from the onset may be
particularly beneficial within this window of opportunity.
Since AZD2171 monotherapy may not increase survival,
future trials of AZD2171 with or without chemotherapy
are planned to validate these findings and test these
hypotheses.
EXPERIMENTAL PROCEDURES
Study Design
The current phase 2 investigational study was approved by the Institu-
tional Review Board at the Dana-Farber/Harvard Cancer Center. Inclu-
sion criteria for this study were the following: pathological diagnosis
of glioblastoma; imaging or pathological evidence of recurrent
glioblastoma; ability to provide informed consent; Mini-Mental Status
Examination (MMSE) score R 15; age R 18; adequate functional
status (Karnofsky Performance ScoreR 60); elapse of 3 months since
prior radiation, 3 weeks since prior non-nitrosourea-based chemother-
apy or 6 weeks since prior nitrosourea-based chemotherapy; treat-
ment with no more than two prior chemotherapy regimens; stable
dose of corticosteroids for at least 5 days prior to the first study MRI
scan; adequate bone marrow (absolute neutrophil count R 1500/ml;
platelet count R 100,000/ml; hemoglobin R 8 g/dl); creatinine within
normal institutional limits or creatinine clearance R 60 ml/min/1.73
m2 for patients with creatinine greater than normal institutional limits.
Exclusion criteria for this study included the following: major surgery
(including craniotomy for tumor resection or biopsy) within 4 weeks;
concurrent use of anticoagulant drugs or antiplatelet drugs; mean cor-
rected QT interval > 470 milliseconds or patients with familial pro-
longed QT syndrome; R1+ proteinuria on two successive urine
dipstick assessments; pregnant women; patients with uncontrolled
hypertension or other serious medical illnesses (including but not
limited to unstable angina, cardiac arrhythmia, active infection, symp-
tomatic congestive heart failure); patients infected with the human
immunodeficiency virus; concurrent use of enzyme-inducing antiepi-
leptic drugs; imaging (CT or MRI) evidence of intratumoral or peritu-
moral hemorrhage deemed significant by the treating physician;
patients with a history of coagulopathy. All patients were provided
blood pressure monitoring devices for use at home. Blood pressure
diaries were recorded for all patients. In patients who developed
hypertension, a standard algorithm for management was followed.
The accrual goal for this trial of 31 patients has been achieved. It is
not placebo controlled.
We are reporting results on the first 16 consecutive patients
accrued; no selection criteria were employed to include patients in
this analysis (for further details, see http://clinicaltrials.gov, identifier
NCT00254943).
Eligible patients received AZD2171 (cediranib, AstraZeneca Phar-
maceuticals, Cheshire, UK) at a dose of 45 mg daily by mouth continu-
ously. There was no maximal length of therapy. Dose-limiting toxicities
were defined as any grade 3 nonhematological or grade 4 hematologi-
cal toxicities. In patients experiencing dose-limiting toxicities,92 Cancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc.AZD2171 could be reduced to 30 mg (dose reduction 1), 20 mg (dose
reduction 2), or 10 mg (dose reduction 3). Patients could also reduce
or terminate administration in consultation with their neuro-oncologist
for any other side effect considered to be related to AZD2171.
Patients were followed by serial neurological and physical examina-
tions every 28 days; dynamic contrast enhanced MRI; diffusion tensor
MRI; perfusion weighted MRI on days5 (plus or minus 2 days)1, +1
(at least 24 hr after the first administration of the AZD2171 and before
the second dose), +26–28, +54–56, and standard contrast-enhanced
cranial MRI at baseline and every 60 days thereafter. In addition
patients’ blood (30 ml) was collected on days 1, 0, +2, +10, +28,
and once every 28 days thereafter for the following assays: circulating
endothelial cells, circulating progenitor cells, and plasma levels of
VEGF-A, sVEGFR1 and -2, PlGF, SDF1a, bFGF, and interleukin-8
(see below).
All patients were treated until there was radiographic or clinical
evidence of disease progression. Patients could withdraw from the
study at any time.
The primary endpoint of this phase 2 study was to determine the
proportion of patients alive and progression-free at 6 months (APF6).
Secondary endpoints include radiographic responses, toxicity, overall
survival, as well as biological and imaging endpoints.
MRI Methodology
Image Acquisition
Each patient underwent scanning on the same 3 Tesla MRI system
(TimTrio, Siemens Medical Solutions, Malvern, PA). All patients were
scanned at two baseline time points, typically 3 to 7 days (average:
5.7) and then 1 day before the first treatment, as well as 1 day and
28 days after the first treatment. (There were two deviations from this:
patients 2 and 11 had the second baseline scan at 2 days before the first
treatment.) Thirteen of 16 patients were also scanned about 56 days af-
ter the first treatment, and 5 of the 16 patients (who had not experienced
progression) were scanned about 112 days after the first treatment.
Each scanning session consisted of the following sequences:
1. Scout. The ‘‘AutoAlign’’ method of producing scout images was
used to improve scan-to-scan reproducibility. Briefly, this
method acquires two low-resolution whole-head scans
(2.5 mm isotropic voxels) at different flip angles within 46 s,
and uses a computer algorithm to compare the current location
of the head with a predefined atlas. This localization is then
used to ensure that the slice prescriptions are identical between
scan sessions, even across many months (Benner et al., 2006;
van der Kouwe et al., 2005). Imaging time: 46 s.
2. T2-weighted images. A single-slab, three-dimensional, T2-
weighted turbo-spin-echo sequence with high sampling
efficiency (‘‘SPACE’’) (Lichy et al., 2005) was used at high
resolution. Specific imaging parameters: 0.9 mm isotropic,
192 slices, 2563 256 matrix, 24 cm FOV, TR 3200 ms, effective
TE 494 ms. Imaging time: 4:30 (minutes:seconds).
3. FLAIR images. Axial fluid-attenuated inversion recovery images
were acquired with TR 10,000 ms, TE 70 ms, and 5 mm slice
thickness, 1 mm interslice gap, and 0.6 mm3 0.45 mm in-plane
resolution; 23 slices, 384 3 512 matrix. Imaging time: 3:02.
4. T1 images. Axial images were obtained prior to the injection
of contrast. TR 600 ms, TE 12 ms, 5 mm slice thickness,
1 mm interslice gap, 0.45 mm in-plane resolution; 23 slices,
384 3 512 matrix. Imaging time: 1:59.
5. Dynamic contrast-enhanced images. This is a series of acquisi-
tions of a 50.6 mm thick slab consisting of 20 slices. All scans
are 2.9 mm 3 2.0 mm in-plane resolution, with a 2.1 mm slice
thickness, 0.4 mm interslice gap, using a fast gradient echo
technique (TR 5.7 ms, TE 2.73 ms). Data to allow computation
of a T1 map of the tissue of interest are initially created using
five different flip angles (2, 5, 10, 15, 30). Then, the same
slab of tissue is sampled with a 10 flip angle every 5.04 s for
252 s (50 time points), and 0.1 mMol/kg of Gd-DTPA was
injected 52 s after the beginning of the acquisition at 5 cc/s.
Imaging time: 4:12.
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echo-planar diffusion-weighted images were acquired with TR
7500 ms, TE 84 ms, and a b-value of 700 s/mm2 in 42 directions
as well as 7 low b-value images (b 0 s/mm2) to allow recon-
struction of the diffusion tensor at each voxel. Resolution was
2 mm isotropic, with a 128 3 128 matrix. Imaging time: 6:30.
7. Dynamic susceptibility contrast imaging. A 75 mm slab of tissue
was imaged using a dual-echo, combined gradient-echo, and
spin-echo echo planar sequence to enable relative vessel size
mapping (Dennie et al., 1998; Pathak et al., 2001; Schmainda
et al., 2004). This sequence acquires two images after each
90 RF excitation: a gradient echo image (TE 34) and a spin
echo image (TE 103); each image had 1.7 mm in-plane resolu-
tion and 5 mm through-plane resolution (128 3 128 matrix).
There was a 2.5 mm interslice gap and 10 slices. 120 blocks
of images were acquired, with a block acquired every 1.33 s.
0.2 mmol/kg of Gd-DTPA was injected at 5 cc/s after 85 s of
imaging. Imaging time: 2:45.
8. Postcontrast T1-weighted imaging. Axial T1-weighted images
were acquired exactly as precontrast, as described above. In
addition, a 3D magnetization prepared rapid gradient echo
(MP-RAGE) volumetric acquisition was performed, with 1 mm
isotropic voxels, TR 2530, TE 3.5 ms, 2563 256 matrix, 176 sli-
ces. Imaging time: 6:06.
Image Analysis
Volumetrics
Enhancing lesions and areas of T2 abnormality on FLAIR images were
quantitatively analyzed by an experienced neuroradiologist blinded to
the order of the scans and treatment status of the patients. The lesions
were outlined using a volumetric approach described previously
(Sorensen et al., 2001) that includes outlining each enhancing voxel
on postcontrast scans and then summing the voxels to calculate an
overall lesion volume.
Map Synthesis: Blood Volume, Blood Flow, and Relative
Vessel Size Maps
Relative cerebral blood volume of larger vessels (gradient echo
images) and smaller vessels (spin echo images) as well as cerebral
blood flow were calculated using a standard deconvolution technique
(Ostergaard et al., 1996), with blood volume corrected for leakage of
the contrast agent across the blood-brain barrier (Boxerman et al.,
2006; Law et al., 2002). These maps are relative and therefore unitless.
Relative vessel size maps were created using the ratio of delta-R2* to
delta-R2, according to published approaches (Dennie et al., 1998;
Pathak et al., 2001; Schmainda et al., 2004). This provides a voxel-
by-voxel estimate of the relative radius of the microvasculature, with
larger vessel diameter corresponding to brighter signal.
Apparent Diffusion Coefficient Maps
Maps of apparent diffusion coefficient (ADC) (Oh et al., 2005) were
created from the low and high b-value images using custom-written
software implementing the standard Steskjal-Tanner diffusion approx-
imation. This provides an estimate of the relative water self-diffusion or
water mobility on a voxel-by-voxel basis; higher values represent
a greater degree of water mobility, and the units of these maps are
in area/time, typically mm2/s.
Permeability Maps
Dynamic contrast-enhanced MRI data were processed using custom-
made software written in Matlab (The MathWorks, Natick, MA), follow-
ing standard published approaches, including maps of Ktrans (corre-
sponding roughly to wash-in rates of the contrast agent) (Tofts et al.,
1999) and ve (extracellular-extravascular volume fraction). These refer-
ences provide highly detailed descriptions of these parameters and
their biophysical meaning. Ktrans does not fully correspond to perme-
ability in each regime, but it is related to the permeability-surface
area product of the capillary bed in non-flow-limited situations.
Synthetic Map Analysis
The outlines generated in the volumetric analysis of the second base-
line (day 1) were coregistered to the synthesized maps (CBV, CBF,vessel size, Ktrans, ADC) and median values across the entire enhanc-
ing lesion (for CBV, CBF, vessel size, and Ktrans) or entire FLAIR lesion
abnormality (for ADC) were computed. As all of the values other than
ADC were considered relative rather than absolute, maps were nor-
malized to each other using an unaffected area of gray and white mat-
ter typically located distantly, such as in the contralateral hemisphere.
Immunohistochemical Analyses in Tissue Specimens
Archival tissues had to be available for patients to enroll in the clinical
trial. Five micron thick paraffin sections were obtained for the 16 pa-
tients. Immunostaining was performed using standard heat antigen
retrieval in citrate buffer unless otherwise specified by the antibody
manufacturer. Detection of the primary antibody was done using the
HRP visualization system from Dako EnVision in combination with
DAB and counterstained with Hematoxilin. The primary antibodies
were as follows: CD31 (DAKO N1596) prediluted antibody; a-SMA
(DAKO M0581) 1:5000; VEGFR1 (R&D Mab321) 7.5 mg/ml; VEGFR2
(Cell Signaling 2479) 1:125; PDGFRa (Cell Signaling 3164) 1:50;
PDGFRb (Cell Signaling 3169) 1:50.
A subset of seven patients diagnosed with recurrent glioblastoma
(diagnosis confirmed by Dr. D. Louis, neuropathologist) for whom
tissue specimens were available from both the initial diagnostic proce-
dure and from a pathologically confirmed recurrence were identified
from the Massachusetts General Hospital Neuropathology database.
Sections from the identified specimen were labeled as described
above and used to determine retention of a given molecular target
at the time of recurrence.
Measurement of Angiogenic Proteins in Plasma
Peripheral blood was obtained with informed consent from patients
with recurrent glioblastoma enrolled in a phase 2 trial of AZD2171 at
base line, 8 hr, 2 days, 9 days, and 28 days following the first dose
of AZD2171 and every 28 days thereafter. Blood was collected in an
EDTA-containing vacutainer, spun down, and plasma was aliquoted,
and frozen immediately. Plasma analysis was carried out for circulating
VEGF, PlGF, soluble VEGFR1, and bFGF using multiplex ELISA plates
from Meso-Scale Discovery (Gaithersburg, MD) as well as soluble
VEGFR2, SDF1-a, and IL-8 from R&D System (Minneapolis, MN).
Every sample was run in duplicate.
Circulating Cell Evaluation by Flow Cytometry
Blood circulating cells were phenotyped and enumerated by flow
cytometric analyses of CD31, CD34, CD45, and CD133 expression
using fluorescence-labeled monoclonal antibodies and a standard
protocol in fresh samples (Duda et al., 2006, 2007). Fluorescence-
labeled isotype-matched nonspecific immunoglobulin G (IgG) anti-
bodies were used as controls. Flow cytometry was performed on
FACSVantage instruments (Becton Dickinson, San Jose, CA), as
described. Cell concentrations were calculated as percentages of
the total number of mononuclear cells after an evaluation of at least
100,000 cellular events. The quantitative analysis end point was the
change in the fraction of CD31brightCD34+CD45 and CD133+CD34+
cells within the mononuclear blood cell population in patients receiving
AZD2171 treatment (see below). Percent values were obtained at
day 1, before initiation of the therapy, and then at 8 hr and 2, 9, 28,
and 56 days after the first ingestion of the drug. Posttreatment values
were compared with pretreatment values in individual patients using
the Wilcoxon signed rank test.
Statistical Analysis
Statistical comparisons between MRI parameters, protein levels, and
cell counts measured on different study days were performed with
a two-tailed paired exact Wilcoxon test (Hollander and Wolfe, 1973)
except for Table S3, where we used a two-tailed, exact binomial
test. The effect of drug holidays on these variables (after log-transfor-
mation) was tested in a mixed effects model (Demidenko, 2004) where
random effect part included a patient-specific intercept and fixed
effect part included a nonlinear function of time from beginning ofCancer Cell 11, 83–95, January 2007 ª2007 Elsevier Inc. 93
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Normalization of Glioblastoma Vasculature in Patientsthe study (B-spline with three knots) and a dummy variable indicating
the history of drug holidays. It was assumed that the effect of transient
drug holidays lasted up to 2 weeks after resuming the use of study
drug; we conducted sensitivity analysis with different values of this
parameter (4 week duration and indefinite duration). The effect of
tumor response on log-transformed cytokine levels or circulating cell
levels was tested in a similar mixed effects model including patient-
specific intercept and a fixed effects part consisting of a B-spline
function of time and the percentage of tumor volume with respect
to baseline measurement. Finally, the effect of log-transformed MRI
parameters and protein levels on vessel size was tested in a mixed
linear model including patient-specific intercept, vessel size at base-
line, and a B-spline function of time. Peak levels of circulating cells
were compared by an exact Wilcoxon test.
Supplemental Data
Supplemental Data include eight tables, two figures, and a movie
and are available at http://www.cancercell.org/cgi/content/full/11/1/
83/DC1/.
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